Innovent Biologics, Inc.

HK$86.35As of Sun 8 Nov 2026, 12:00 UTC
HKEX:1801Healthcare
Country Hong Kong
PE (Fwd) •••
TSR 8Y CAGR 22.84%
Div yield —
ROE 7.01%
Biotechnology
Beta (5Y) 0.36
PE TTM 107.5
TSR TTM (0.75%)
Mkt cap HK$150.3B
ROIC 30.16%
SE Grade™
Value
Quality
Moat
Consensus
Reference
$104
19.89%
(92.62%)
Hold 11|0|9|9|11
4Q25
1Q26
2Q26
3Q26
Earnings per share¥
0.82
0.78
0.77
0.76
4.59%
3.93%
5.18%
(5.20%)
Revenue¥B
8.126
8.195
8.325
8.798
(1.44%)
0.65%
0.32%
5.23%
Peers (US$19.18B)
Cap (US$)
PE
10.23B
—
Capital
TTM
5Y
10Y
Leveragex
1.475
—
—
EBIT/Intx
0.576
0.395
0.335
Own earn%
101.41
12.13
12.91
Sh yield%
24.46
13.43
14.07
Owners
Insiders/Inst%
0.61
27.12
Short interest%
2.36
SBC / revenue%
0.50
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
6
Op margin range%
2–7
$1 testx
—
Incr. ROIC%
28